Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oxford University

- PMLiVE

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

- PMLiVE

MIT researchers develop AI model to detect Parkinson’s from breathing patterns

The tool uses a series of connected algorithms that can assess if someone has PD from their nocturnal breathing

- PMLiVE

Michael J Fox Foundation awards Koneksa second research grant

The grant will be used to evaluate whether digital biomarkers can help to predict the different stages of Parkinson’s disease

- PMLiVE

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

NRG received a £2.68m Innovative UK award to help fund research into treatments for Parkinson’s disease, motor neurone disease and other neurodegenerative diseases

- PMLiVE

LifeArc partners with UK Dementia Research Institute

Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040

- PMLiVE

NRG Therapeutics receives £2.68m Innovate UK Award

The funds will be used for research into new treatments for Parkinson’s and motor neurone disease

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

- PMLiVE

The Michael J Fox Foundation gives Asceneuron second research grant

Parkinson's disease affects an estimated seven to ten million people worldwide

- PMLiVE

AbbVie ends partnership with BioArctic to develop treatment for Parkinson’s disease

Results supporting phase 2 trials were presented at the International Congress of Parkinson’s Disease and Movement Disorders in September 2021

- PMLiVE

Parkinson’s UK and Domainex announce new collaboration

Parkinson’s Virtual Biotech plans to invest up to £3m in the project

- PMLiVE

SMC approves Parkinson’s disease treatment Ongentys

The once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland

- PMLiVE

Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease

Researchers identified eight Parkinson’s disease states, with seven outcomes associated with terminal Parkinson’s disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links